PCMC
IOVA icon

Planning Capital Management Corporation’s Iovance Biotherapeutics IOVA Stock Holding History

Planning Capital Management Corporation’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$235 Hold
25
– – ﹤0.01% 694
2024
Q2 		$201 Buy
+25
New +$268 ﹤0.01% 648

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Planning Capital Management Corporation's IOVA Position: Q3 2024 in Review

Planning Capital Management Corporation held its Iovance Biotherapeutics (IOVA) position steady in Q3 2024 at 25 shares worth $235. The position accounts for ﹤0.01% of the portfolio, ranked #694.

Planning Capital Management Corporation first reported a position in IOVA in Q2 2024 and has held it in 2 quarters since. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Planning Capital Management Corporation held 25 shares of Iovance Biotherapeutics worth $235 as of Q3 2024.
  • Planning Capital Management Corporation left its Iovance Biotherapeutics share count unchanged in Q3 2024.
  • Iovance Biotherapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #694 holding.
  • Planning Capital Management Corporation first reported a position in Iovance Biotherapeutics in Q2 2024 and has held it in 2 quarters since.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.